Bruker (NASDAQ:BRKR) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Key Points

• Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.32 EPS, missing analysts' consensus estimates of $0.43 by $0.11.
• The company announced a quarterly dividend of $0.05 per share, resulting in an annualized dividend of $0.20 with a yield of 0.5%.
• Brokerage firms have reduced their price targets for Bruker, with Bank of America lowering its target from $61.00 to $50.00 while maintaining a "buy" rating.

Bruker (NASDAQ:BRKR - Get Free Report) released its earnings results on Monday. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.11), Zacks reports. Bruker had a return on equity of 19.47% and a net margin of 2.31%.

Bruker Stock Performance

BRKR opened at $37.99 on Monday. The firm has a fifty day moving average price of $39.94 and a 200 day moving average price of $43.35. Bruker has a 1 year low of $34.10 and a 1 year high of $72.94. The stock has a market cap of $5.76 billion, a P/E ratio of 73.06, a P/E/G ratio of 2.56 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Monday, June 16th. Bruker's payout ratio is 38.46%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BRKR. Bank of America dropped their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. UBS Group dropped their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Barclays reduced their price objective on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. The Goldman Sachs Group dropped their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $52.89.

Insider Buying and Selling

In other news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction dated Friday, June 6th. The shares were acquired at an average cost of $38.36 per share, with a total value of $100,042.88. Following the purchase, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. The trade was a 0.01% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 27.30% of the company's stock.

Hedge Funds Weigh In On Bruker

A number of large investors have recently bought and sold shares of BRKR. Royal Bank of Canada increased its position in shares of Bruker by 8.3% in the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock valued at $5,148,000 after buying an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Bruker during the first quarter worth about $262,000. Goldman Sachs Group Inc. raised its position in shares of Bruker by 107.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after purchasing an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock valued at $15,285,000 after buying an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth boosted its holdings in Bruker by 115.0% in the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock worth $469,000 after buying an additional 6,008 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.